Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 3
1978 1
1982 1
1985 1
1998 1
1999 1
2002 1
2005 2
2006 2
2009 1
2010 1
2012 1
2019 1
2020 1
2021 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Effect of the new SARS-CoV-2 variant B.1.1.7 on children and young people.
Brookman S, Cook J, Zucherman M, Broughton S, Harman K, Gupta A. Brookman S, et al. Lancet Child Adolesc Health. 2021 Apr;5(4):e9-e10. doi: 10.1016/S2352-4642(21)00030-4. Epub 2021 Feb 10. Lancet Child Adolesc Health. 2021. PMID: 33581054 Free PMC article. No abstract available.
An epidemiologic surveillance of Shiga-like toxin-producing Escherichia coli infection in Argentinean children: risk factors and serum Shiga-like toxin 2 values.
López EL, Contrini MM, Glatstein E, Ayala SG, Santoro R, Ezcurra G, Teplitz E, Matsumoto Y, Sato H, Sakai K, Katsuura Y, Hoshide S, Morita T, Harning R, Brookman S. López EL, et al. Among authors: brookman s. Pediatr Infect Dis J. 2012 Jan;31(1):20-4. doi: 10.1097/INF.0b013e31822ea6cf. Pediatr Infect Dis J. 2012. PMID: 21829137
Tailored anticoagulant treatment after a first venous thromboembolism: protocol of the Leiden Thrombosis Recurrence Risk Prevention (L-TRRiP) study - cohort-based randomised controlled trial.
Burggraaf-van Delft JLI, van Rein N, Bemelmans RHH, van den Berg JK, Bruggeman CY, Cloos-van Balen M, Coppens M, Eefting M, Ende-Verhaar Y, van Es N, van Guldener C, de Jong WK, Kleijwegt F, Koster T, Kroon C, Kuipers S, Leentjens J, Luijten D, Mairuhu ATA, Meijer K, van de Ree MA, Roos R, Schrover I, Swart-Heikens J, van der Velden AWG, van den Akker-van Marle EM, le Cessie S, Geersing GJ, Middeldorp S, Huisman MV, Klok FA, Cannegieter SC; L-TRRiP investigators. Burggraaf-van Delft JLI, et al. BMJ Open. 2024 Mar 23;14(3):e078676. doi: 10.1136/bmjopen-2023-078676. BMJ Open. 2024. PMID: 38521524 Free PMC article.
Safety and pharmacokinetics of urtoxazumab, a humanized monoclonal antibody, against Shiga-like toxin 2 in healthy adults and in pediatric patients infected with Shiga-like toxin-producing Escherichia coli.
López EL, Contrini MM, Glatstein E, González Ayala S, Santoro R, Allende D, Ezcurra G, Teplitz E, Koyama T, Matsumoto Y, Sato H, Sakai K, Hoshide S, Komoriya K, Morita T, Harning R, Brookman S. López EL, et al. Among authors: brookman s. Antimicrob Agents Chemother. 2010 Jan;54(1):239-43. doi: 10.1128/AAC.00343-09. Epub 2009 Oct 12. Antimicrob Agents Chemother. 2010. PMID: 19822704 Free PMC article. Clinical Trial.
18 results